The abundance of PD-1+CD8+ TILs in most HNSCC patients, 84.1% of the HPV− HNSCC microenvironments were rich in CD8+ TILs in this study, provides the basis for immunotherapy. The gene discussed is CD8A; the disease is head and neck squamous cell carcinoma.